Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose imatinib with response-guided switch to nilotinib in newly diagnosed chronic phase CML
ACTRN12607000325404Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib and nilotinib in chronic myelogenous leukemia (CML), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Rate of major molecular response and Duration of major molecular response. Started Nov 2007; status: completed.
02
Drugs
imatinibnilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ACTRN12607000325404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000325404.